HighVista Strategies LLC
Reported holdings as of Q2 2026, from 31 quarterly filings.
This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
Download these holdings as CSV
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| INVESCO DB COMMDY INDX TRCK | DBC | $28.2M | 1,057,238 | -2.02pp | 31q | HELD | |
| ABIVAX SA | ABVX | $15.1M | 113,031 | -0.05pp | 10q | HELD | |
| REVOLUTION MEDICINES INC | RVMD | $12.5M | 66,983 | +1.00pp | 12q | -3.4%-$435.6K | |
| DEFINIUM THERAPEUTICS INC | DFTX | $11.4M | 242,884 | +1.64pp | 2q | +30.7%+$2.7M | |
| IMMUNOVANT INC | IMVT | $10.7M | 277,873 | +0.90pp | 6q | +23.4%+$2.0M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $10.1M | 30,210 | -0.04pp | 8q | +14.8%+$1.3M | |
| RELAY THERAPEUTICS INC | RLAY | $9.5M | 506,235 | +1.00pp | 5q | +20.0%+$1.6M | |
| ALKERMES PLC | ALKS | $9.4M | 179,256 | +1.43pp | 7q | +144.9%+$5.6M | |
| VAXCYTE INC | PCVX | $8.7M | 149,739 | -0.02pp | 17q | +20.1%+$1.5M | |
| TANGO THERAPEUTICS INC | TNGX | $8.1M | 260,070 | +1.25pp | 2q | +149.6%+$4.9M | |
| LIQUIDIA CORPORATION | LQDA | $7.8M | 97,896 | +0.74pp | 9q | -1.9%-$147.3K | |
| COGENT BIOSCIENCES INC | COGT | $7.3M | 188,780 | -0.43pp | 16q | -4.2%-$320.1K | |
| STRUCTURE THERAPEUTICS INC | GPCR | $7.0M | 130,784 | -0.05pp | 12q | +5.5%+$369.0K | |
| ENLIVEN THERAPEUTICS INC | ELVN | $7.0M | 137,866 | +0.80pp | 13q | +88.6%+$3.3M | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $6.9M | 386,080 | +0.23pp | 3q | +9.7%+$610.6K | |
| SPYRE THERAPEUTICS INC | SYRE | $6.9M | 77,807 | -0.46pp | 11q | -46.8%-$6.1M | |
| LB PHARMACEUTICALS INC | LBRX | $6.9M | 211,511 | +0.38pp | 3q | +21.8%+$1.2M | |
| CYTOKINETICS INC | CYTK | $6.6M | 78,003 | +0.45pp | 8q | +33.0%+$1.6M | |
| C4 THERAPEUTICS INC | CCCC | $6.3M | 1,348,136 | - | new | NEW | |
| TYRA BIOSCIENCES INC | TYRA | $5.9M | 184,774 | -0.04pp | 9q | +40.7%+$1.7M | |
| ALUMIS INC | ALMS | $5.6M | 199,968 | +0.60pp | 2q | +77.1%+$2.4M | |
| PHARVARIS N V | PHVS | $5.5M | 160,494 | +0.50pp | 3q | +64.0%+$2.2M | |
| TARSUS PHARMACEUTICALS INC | TARS | $5.5M | 87,060 | +0.23pp | 5q | +65.9%+$2.2M | |
| COMPASS PATHWAYS PLC | CMPS | $5.3M | 371,120 | +0.64pp | 3q | +1.9%+$95.7K | |
| DIANTHUS THERAPEUTICS INC | DNTH | $5.0M | 51,125 | +0.31pp | 8q | +43.7%+$1.5M | |
| NURIX THERAPEUTICS INC | NRIX | $4.9M | 203,739 | +0.16pp | 2q | -10.1%-$553.3K | |
| AXSOME THERAPEUTICS INC | AXSM | $4.9M | 20,183 | +0.17pp | 16q | -1.2%-$62.2K | |
| TRAVERE THERAPEUTICS INC | TVTX | $4.9M | 86,233 | +0.82pp | 2q | +137.4%+$2.8M | |
| VERA THERAPEUTICS INC | VERA | $4.5M | 105,907 | +0.27pp | 2q | +53.0%+$1.6M | |
| NVIDIA CORPORATION | NVDA | $4.4M | 21,792 | -0.09pp | 7q | -2.8%-$125.7K | |
| GH RESEARCH PLC | GHRS | $4.3M | 158,770 | +0.15pp | 5q | -25.5%-$1.5M | |
| PALISADE BIO INC | PALI | $4.2M | 2,030,927 | -0.01pp | 3q | +0.6%+$24.2K | |
| ARGENX SE | ARGX | $4.2M | 4,561 | -0.03pp | 25q | -7.3%-$331.2K | |
| MAZE THERAPEUTICS INC | MAZE | $4.1M | 136,572 | +0.11pp | 3q | +36.8%+$1.1M | |
| OCULAR THERAPEUTIX INC | OCUL | $4.0M | 408,534 | -0.12pp | 9q | -7.5%-$324.4K | |
| ORUKA THERAPEUTICS INC | ORKA | $4.0M | 41,902 | -0.16pp | 2q | -46.9%-$3.5M | |
| DYNE THERAPEUTICS INC | DYN | $3.8M | 171,961 | -0.04pp | 3q | -6.0%-$243.6K | |
| EDGEWISE THERAPEUTICS INC | EWTX | $3.7M | 90,996 | +0.04pp | 8q | -1.0%-$38.0K | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $3.7M | 187,946 | -0.16pp | 2q | -3.1%-$117.0K | |
| INSMED INC | INSM | $3.3M | 31,256 | -0.34pp | 12q | +28.5%+$739.9K | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $3.2M | 86,964 | -0.05pp | 5q | -2.7%-$90.5K | |
| AMAZON COM INC | AMZN | $3.2M | 13,397 | -0.56pp | 17q | -40.2%-$2.1M | |
| INVENTIVA SA | IVA | $3.1M | 831,442 | -0.23pp | 2q | +35.0%+$815.6K | |
| TALEN ENERGY CORP | TLN | $3.1M | 8,148 | +0.44pp | 7q | +161.3%+$1.9M | |
| RELMADA THERAPEUTICS INC | RLMD | $3.1M | 445,799 | - | new | NEW | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $3.0M | 24,460 | -0.30pp | 11q | -27.7%-$1.2M | |
| ERASCA INC | ERAS | $2.9M | 160,328 | -0.14pp | 2q | -11.5%-$380.0K | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $2.9M | 159,885 | -0.06pp | 18q | +19.1%+$471.3K | |
| HEWLETT PACKARD ENTERPRISE C | HPE | $2.7M | 59,081 | +0.02pp | 8q | -34.3%-$1.4M | |
| MINERALYS THERAPEUTICS INC | MLYS | $2.3M | 86,085 | +0.18pp | 5q | +84.0%+$1.1M | |
| GUARDANT HEALTH INC | GH | $2.3M | 15,419 | -0.07pp | 7q | -34.0%-$1.2M | |
| AVALO THERAPEUTICS INC | AVTX | $2.3M | 122,610 | +0.27pp | 4q | +109.2%+$1.2M | |
| JAMES HARDIE INDS PLC | JHX | $2.2M | 85,198 | +0.17pp | 2q | +29.9%+$513.1K | |
| EYEPOINT INC | EYPT | $2.2M | 155,704 | -0.14pp | 2q | -14.9%-$390.9K | |
| MASTEC INC | MTZ | $2.1M | 5,137 | +0.17pp | 6q | +41.6%+$628.3K | |
| XENON PHARMACEUTICALS INC | XENE | $2.1M | 35,318 | -0.30pp | 2q | -28.0%-$828.9K | |
| RBC BEARINGS INC | RBC | $2.1M | 3,223 | +0.07pp | 6q | +21.0%+$360.7K | |
| VISA INC | V | $2.0M | 5,961 | -0.13pp | 18q | -16.5%-$404.8K | |
| ASSEMBLY BIOSCIENCES INC | ASMB | $2.0M | 73,405 | -0.11pp | 2q | -1.8%-$36.5K | |
| STOKE THERAPEUTICS INC | STOK | $2.0M | 61,316 | -0.11pp | 3q | -2.1%-$42.6K | |
| OLEMA PHARMACEUTICALS INC | OLMA | $2.0M | 160,167 | -0.03pp | 13q | +36.2%+$532.5K | |
| ROCKET COS INC | RKT | $2.0M | 125,530 | +0.09pp | 3q | +35.8%+$521.3K | |
| XPO INC | XPO | $2.0M | 9,623 | -0.03pp | 13q | +7.8%+$143.7K | |
| WESTERN DIGITAL CORP | WDC | $1.9M | 3,050 | +0.14pp | 2q | -25.6%-$670.7K | |
| CORE SCIENTIFIC INC NEW | CORZ | $1.9M | 75,712 | +0.01pp | 8q | -26.8%-$708.8K | |
| TEXAS INSTRS INC | TXN | $1.9M | 6,500 | - | new | NEW | |
| KBR INC | KBR | $1.9M | 54,206 | +0.03pp | 4q | +37.6%+$511.0K | |
| FLOWSERVE CORP | FLS | $1.9M | 24,958 | -0.08pp | 4q | HELD | |
| ALPHABET INC | GOOG | $1.8M | 5,127 | -0.02pp | 4q | -6.4%-$123.7K | |
| SEAGATE TECHNOLOGY HLDNGS PL | STX | $1.8M | 1,870 | +0.10pp | 2q | -35.5%-$994.0K | |
| MIRUM PHARMACEUTICALS INC | MIRM | $1.7M | 14,892 | flat | 2q | -4.3%-$78.6K | |
| DNOW INC | DNOW | $1.7M | 132,900 | - | new | NEW | |
| ON SEMICONDUCTOR CORP | ON | $1.7M | 18,200 | -0.09pp | 2q | -35.0%-$926.5K | |
| NUCOR CORP | NUE | $1.7M | 7,600 | - | new | NEW | |
| USA TODAY CO INC | TDAY | $1.6M | 188,500 | - | new | NEW | |
| BROADCOM INC | AVGO | $1.6M | 4,199 | -0.12pp | 8q | -25.0%-$528.8K | |
| CALUMET INC | CLMT | $1.6M | 44,000 | - | new | NEW | |
| QNITY ELECTRONICS INC | Q | $1.6M | 9,700 | - | new | NEW | |
| KODIAK SCIENCES INC | KOD | $1.6M | 40,590 | -0.10pp | 2q | -6.8%-$116.1K | |
| CREDO TECHNOLOGY GROUP HOLDI | CRDO | $1.6M | 5,800 | - | new | NEW | |
| KNIGHT-SWIFT TRANSN HLDGS IN | KNX | $1.6M | 20,100 | -0.01pp | 2q | -12.2%-$218.0K | |
| BRINKS CO | BCO | $1.6M | 16,414 | - | new | NEW | |
| ASTERA LABS INC | ALAB | $1.5M | 3,198 | - | new | NEW | |
| S&P GLOBAL INC | SPGI | $1.5M | 3,782 | - | new | NEW | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $1.5M | 2,852 | -0.03pp | 14q | +9.8%+$136.4K | |
| EQUIFAX INC | EFX | $1.5M | 9,572 | - | new | NEW | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $1.5M | 13,657 | -0.06pp | 11q | -18.7%-$348.5K | |
| SAVARA INC | SVRA | $1.5M | 242,379 | -0.04pp | 2q | -3.4%-$53.1K | |
| DOMINOS PIZZA INC | DPZ | $1.5M | 4,991 | - | new | NEW | |
| BELITE BIO INC | BLTE | $1.5M | 9,554 | -0.02pp | 2q | +18.9%+$234.2K | |
| MICRON TECHNOLOGY INC | MU | $1.5M | 1,260 | -0.02pp | 2q | -66.8%-$2.9M | |
| CIENA CORP | CIEN | $1.4M | 2,925 | -0.24pp | 3q | -44.7%-$1.2M | |
| CELCUITY INC | CELC | $1.4M | 13,472 | -0.09pp | 4q | +2.8%+$38.4K | |
| QXO INC | QXO | $1.4M | 81,420 | +0.18pp | 7q | +209.3%+$952.1K | |
| IMMUNOCORE HLDGS PLC | IMCR | $1.4M | 43,185 | -0.18pp | 3q | -26.4%-$492.5K | |
| CG ONCOLOGY INC | CGON | $1.3M | 18,867 | -0.07pp | 8q | -5.3%-$74.4K | |
| US FOODS HLDG CORP | USFD | $1.3M | 13,000 | - | new | NEW | |
| TRANSDIGM GROUP INC | TDG | $1.3M | 985 | -0.07pp | 3q | -14.0%-$213.1K | |
| LUMENTUM HLDGS INC | LITE | $1.3M | 1,517 | -0.31pp | 4q | -51.3%-$1.4M | |
| FIRSTENERGY CORP | FE | $1.2M | 26,100 | - | new | NEW | |
| MASTERCARD INCORPORATED | MA | $1.2M | 2,384 | -0.12pp | 6q | -18.5%-$277.3K | |
| ENTERGY CORP NEW | ETR | $1.2M | 10,628 | -0.14pp | 5q | -21.4%-$333.1K | |
| KRYSTAL BIOTECH INC | KRYS | $1.2M | 3,260 | +0.15pp | 2q | +78.7%+$533.7K | |
| MOODYS CORP | MCO | $1.2M | 2,670 | - | new | NEW | |
| APPLIED MATLS INC | AMAT | $1.2M | 1,640 | - | new | NEW | |
| XCEL ENERGY INC | XEL | $1.2M | 14,758 | -0.01pp | 3q | +17.5%+$176.7K | |
| NEXTERA ENERGY INC | NEE | $1.2M | 13,338 | -0.02pp | 4q | +20.3%+$197.7K | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $1.1M | 2,095 | +0.01pp | 3q | +38.4%+$314.8K | |
| GOLAR LNG LTD | GLNG | $1.1M | 22,100 | - | new | NEW | |
| DOORDASH INC | DASH | $1.1M | 5,810 | -0.03pp | 2q | -13.4%-$166.1K | |
| ICICI BANK LIMITED | IBN | $1.0M | 35,884 | +0.04pp | 14q | +28.7%+$232.2K | |
| DISC MEDICINE INC | IRON | $1.0M | 14,219 | - | new | NEW | |
| AMPHENOL CORP | APH | $1.0M | 5,781 | -0.11pp | 6q | -40.9%-$705.3K | |
| UNITY SOFTWARE INC | U | $1.0M | 35,163 | -0.15pp | 5q | -44.0%-$788.8K | |
| FERGUSON ENTERPRISES INC | FERG | $990.4K | 4,173 | -0.08pp | 5q | -10.7%-$118.7K | |
| TREVI THERAPEUTICS INC | TRVI | $989.1K | 53,033 | +0.05pp | 3q | -0.9%-$9.2K | |
| STMICROELECTRONICS N V | STM | $988.5K | 13,200 | - | new | NEW | |
| SEPTERNA INC | SEPN | $982.5K | 29,337 | - | new | NEW | |
| FULL TRUCK ALLIANCE CO LTD | YMM | $981.3K | 120,847 | +0.05pp | 3q | +56.6%+$354.5K | |
| BRIDGEBIO PHARMA INC | BBIO | $979.9K | 13,156 | -0.79pp | 12q | -73.5%-$2.7M | |
| ARM HOLDINGS PLC | ARM | $957.3K | 2,700 | - | new | NEW | |
| TAPESTRY INC | TPR | $951.5K | 6,500 | - | new | NEW | |
| NEW ORIENTAL ED & TECHNOLOGY | EDU | $942.9K | 20,537 | +0.02pp | 3q | +66.7%+$377.4K | |
| SILICON MOTION TECHNOLOGY CO | SIMO | $933.3K | 2,800 | - | new | NEW | |
| API GROUP CORP | APG | $929.9K | 21,958 | -0.09pp | 5q | -17.6%-$199.0K | |
| UROGEN PHARMA LTD | URGN | $918.8K | 24,968 | +0.08pp | 4q | -5.8%-$56.7K | |
| MICROSOFT CORP | MSFT | $900.1K | 2,413 | -0.45pp | 17q | -62.6%-$1.5M | |
| ZYMEWORKS INC | ZYME | $889.1K | 34,013 | -0.03pp | 2q | HELD | |
| ADVANCED ENERGY INDS | AEIS | $835.2K | 2,240 | - | new | NEW | |
| KASPI KZ JSC | KSPI | $814.4K | 9,400 | - | new | NEW | |
| HDFC BANK LTD | HDB | $798.8K | 30,927 | flat | 14q | +18.4%+$124.0K | |
| VISTRA CORP | VST | $777.3K | 4,900 | - | new | NEW | |
| JANUX THERAPEUTICS INC | JANX | $743.1K | 48,376 | -0.02pp | 9q | -2.0%-$15.5K | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $708.5K | 20,905 | -0.02pp | 5q | +4.2%+$28.4K | |
| META PLATFORMS INC | META | $654.5K | 1,162 | -0.13pp | 7q | -33.3%-$326.7K | |
| MBX BIOSCIENCES INC | MBX | $642.2K | 11,634 | +0.05pp | 2q | +1.4%+$8.9K | |
| NU HLDGS LTD | NU | $640.9K | 47,970 | -0.05pp | 11q | -3.2%-$21.4K | |
| CYTOMX THERAPEUTICS INC | CTMX | $636.9K | 169,831 | -0.23pp | 4q | -41.0%-$443.3K | |
| MERCADOLIBRE INC | MELI | $636.5K | 375 | -0.06pp | 4q | -13.8%-$101.8K | |
| CONSTELLATION ENERGY CORP | CEG | $618.4K | 2,490 | -0.30pp | 7q | -56.7%-$810.2K | |
| NEKTAR THERAPEUTICS | NKTR | $607.9K | 8,708 | -0.15pp | 3q | -40.2%-$408.2K | |
| AKAMAI TECHNOLOGIES INC | AKAM | $579.2K | 4,900 | - | new | NEW | |
| XENCOR INC | XNCR | $431.8K | 26,822 | -0.08pp | 2q | -49.4%-$422.2K | |
| KYMERA THERAPEUTICS INC | KYMR | $427.8K | 3,731 | +0.01pp | 4q | -1.4%-$6.2K | |
| PDD HOLDINGS INC | PDD | $419.5K | 5,500 | -0.10pp | 2q | -20.3%-$106.8K | |
| JD.COM INC | JD | $360.9K | 14,163 | -0.03pp | 17q | +5.2%+$17.8K | |
| BANCO BRADESCO S A | BBD | $357.9K | 103,132 | -0.13pp | 10q | -50.5%-$364.8K |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $307.5M | 70.1% |
| Capital Markets | $28.2M | 6.4% |
| Semiconductors & Electronics | $24.4M | 5.6% |
| Business Services | $12.9M | 2.9% |
| Utilities | $9.3M | 2.1% |
| Banks & Lending | $6.8M | 1.5% |
| Other sectors | $49.5M | 11.3% |
What the disclosed book did
This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.
| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +22.9% | +14.8% | +8.1% | 97% |
| Q1 2026 | +2.8% | -4.6% | +7.5% | 98% |
| Q4 2025 | +29.9% | +2.4% | +27.6% | 99% |
| Q3 2025 | +20.3% | +7.8% | +12.5% | 99% |
| Q2 2025 | +11.4% | +10.5% | +1.0% | 100% |
| Q1 2025 | -7.7% | -4.6% | -3.2% | 98% |
| Q4 2024 | -4.8% | +2.1% | -6.9% | 100% |
| Q3 2024 | +7.7% | +5.4% | +2.3% | 99% |
Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $438.6M | 147 | 29 | 50 | 64 | 38 | 28.2% | 45 |
| Q1 2026 | $362.2M | 156 | 35 | 46 | 71 | 24 | 27.2% | 45 |
| Q4 2025 | $388.3M | 145 | 33 | 26 | 86 | 36 | 28.1% | 48 |
| Q3 2025 | $408.0M | 148 | 29 | 78 | 38 | 27 | 29.1% | 45 |
| Q2 2025 | $272.1M | 146 | 29 | 49 | 55 | 31 | 27.3% | 45 |
| Q1 2025 | $259.5M | 148 | 35 | 39 | 27 | 24 | 25.8% | 45 |
| Q4 2024 | $268.8M | 137 | 26 | 41 | 37 | 31 | 26.3% | 45 |
| Q3 2024 | $290.0M | 142 | 37 | 46 | 48 | 32 | 25.5% | 45 |
| Q2 2024 | $273.8M | 137 | 34 | 27 | 41 | 28 | 29.4% | 45 |
| Q1 2024 | $280.4M | 131 | 40 | 28 | 35 | 35 | 28.7% | 45 |
| Q4 2023 | $275.6M | 126 | 26 | 63 | 12 | 32 | 29.5% | 45 |
| Q3 2023 | $216.1M | 132 | 38 | 33 | 47 | 40 | 35.1% | 45 |
| Q2 2023 | $218.6M | 134 | 55 | 47 | 23 | 29 | 33.7% | 45 |
| Q1 2023 | $122.8M | 108 | 37 | 19 | 19 | 34 | 29.1% | 45 |
| Q4 2022 | $168.5M | 105 | 26 | 27 | 30 | 34 | 40.7% | 45 |
| Q3 2022 | $175.1M | 113 | 19 | 29 | 20 | 16 | 36.6% | 45 |
| Q2 2022 | $165.6M | 110 | 39 | 43 | 18 | 15 | 40.9% | 46 |
| Q1 2022 | $157.3M | 86 | 39 | 16 | 23 | 22 | 45.1% | 46 |
| Q4 2021 | $125.6M | 69 | 16 | 24 | 10 | 74 | 47.5% | 45 |
| Q3 2021 | $151.1M | 127 | 39 | 47 | 18 | 28 | 48.8% | 46 |
| Q2 2021 | $141.0M | 116 | 37 | 32 | 7 | 46 | 55.7% | 47 |
| Q1 2021 | $134.6M | 125 | 39 | 27 | 28 | 31 | 55.1% | 47 |
| Q4 2020 | $156.6M | 117 | 34 | 35 | 16 | 30 | 59.2% | 47 |
| Q3 2020 | $137.2M | 113 | 47 | 29 | 15 | 34 | 68.5% | 47 |
| Q2 2020 | $120.8M | 100 | 60 | 11 | 11 | 25 | 72.0% | 45 |
| Q1 2020 | $108.0M | 65 | 11 | 10 | 18 | 65 | 78.0% | 45 |
| Q4 2019 | $131.8M | 119 | 33 | 15 | 29 | 40 | 54.1% | 45 |
| Q3 2019 | $146.5M | 126 | 58 | 9 | 30 | 40 | 52.4% | 45 |
| Q2 2019 | $195.4M | 108 | 28 | 23 | 31 | 32 | 56.5% | 45 |
| Q1 2019 | $122.6M | 112 | 50 | 38 | 9 | 51 | 34.6% | 45 |
| Q4 2018 | $115.6M | 113 | 0 | 0 | 0 | 0 | 48.4% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.